Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
12 2020
Historique:
received: 11 07 2020
revised: 03 09 2020
accepted: 10 09 2020
pubmed: 8 10 2020
medline: 26 11 2020
entrez: 7 10 2020
Statut: ppublish

Résumé

Most reports on the declining incidence of myocardial infarction (MI) during the COVID-19 have either been anecdotal, survey results or geographically limited to areas with lockdowns. We examined the incidence of MI during the COVID-19 pandemic in Sweden, which has remained an open society with a different public health approach fighting COVID-19. We assessed the incidence rate (IR) as well as the incidence rate ratios (IRRs) of all MI referred for coronary angiography in Sweden using the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR), during the COVID-19 pandemic in Sweden (1 March 2020-7 May 2020) in relation to the same days 2015-2019. A total of 2443 MIs were referred for coronary angiography during the COVID-19 pandemic resulting in an IR 36 MIs/day (204 MIs/100 000 per year) compared with 15 213 MIs during the reference period with an IR of 45 MIs/day (254 MIs/100 000 per year) resulting in IRR of 0.80, 95% CI (0.74 to 0.86), p<0.001. Results were consistent in all investigated patient subgroups, indicating no change in patient category seeking cardiac care. Kaplan-Meier event rates for 7-day case fatality were 439 (2.3%) compared with 37 (2.9%) (HR: 0.81, 95% CI (0.58 to 1.13), p=0.21). Time to percutaneous coronary intervention (PCI) was shorter during the pandemic and PCI was equally performed, indicating no change in quality of care during the pandemic. The COVID-19 pandemic has significantly reduced the incidence of MI referred for invasive treatment strategy. No differences in overall short-term case fatality or quality of care indicators were observed.

Identifiants

pubmed: 33023905
pii: heartjnl-2020-317685
doi: 10.1136/heartjnl-2020-317685
pmc: PMC7677488
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1812-1818

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

N Engl J Med. 2020 Jul 2;383(1):88-89
pubmed: 32343497
N Engl J Med. 2018 Jan 25;378(4):345-353
pubmed: 29365305
Am J Cardiol. 2012 Feb 15;109(4):502-5
pubmed: 22154089
N Engl J Med. 2008 Jan 31;358(5):475-83
pubmed: 18234752
BMJ. 2018 Dec 12;363:k4811
pubmed: 30541902
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
Eur Heart J. 2020 Jun 7;41(22):2083-2088
pubmed: 32412631
Lancet. 1991 Sep 14;338(8768):660-1
pubmed: 1679475
Circ Cardiovasc Qual Outcomes. 2020 Apr;13(4):e006631
pubmed: 32182131
Inflamm Res. 2012 Jun;61(6):591-8
pubmed: 22373653
Eur Heart J. 2020 May 14;41(19):1852-1853
pubmed: 32297932
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
N Engl J Med. 2020 Jul 30;383(5):496-498
pubmed: 32348640
Heart. 2010 Oct;96(20):1617-21
pubmed: 20801780
JAMA Cardiol. 2018 Nov 1;3(11):1081-1089
pubmed: 30422202
J Am Coll Cardiol. 1997 Nov 1;30(5):1174-80
pubmed: 9350911
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
Eur Heart J. 2011 Apr;32(8):1006-11
pubmed: 21196446

Auteurs

Moman A Mohammad (MA)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.

Sasha Koul (S)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.

Göran K Olivecrona (GK)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.

Matthias Gӧtberg (M)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.

Patrik Tydén (P)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.

Erik Rydberg (E)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.

Fredrik Scherstén (F)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.

Joakim Alfredsson (J)

Department of Cardiology, Linköping University, Linköping, Sweden.

Peter Vasko (P)

Department of Medicine, Växjö Hospital, Växjö, Sweden.

Elmir Omerovic (E)

Department of Cardiology, Department of Molecular and Clinical Medicine, Department of Cardiology, Sahlgrenska University Hospital, Institute of Medicine, Department of Molecular and Clinical Medicine,Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Oskar Angerås (O)

Department of Cardiology, Department of Molecular and Clinical Medicine, Department of Cardiology, Sahlgrenska University Hospital, Institute of Medicine, Department of Molecular and Clinical Medicine,Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Ole Fröbert (O)

Department of Cardiology, Faculty of Health, Örebro University, Örebro, Sweden.

Fredrik Calais (F)

Department of Cardiology, Faculty of Health, Örebro University, Örebro, Sweden.

Sebastian Völz (S)

Department of Cardiology, Department of Molecular and Clinical Medicine, Department of Cardiology, Sahlgrenska University Hospital, Institute of Medicine, Department of Molecular and Clinical Medicine,Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Anders Ulvenstam (A)

Department of Cardiology, Östersund Hospital, Östersund, Sweden.

Dimitrios Venetsanos (D)

Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.

Troels Yndigegn (T)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.

Jonas Oldgren (J)

Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Giovanna Sarno (G)

Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Per Grimfjärd (P)

Department of Internal Medicine, Västmanlands Sjuk, Lund, Sweden.

Jonas Persson (J)

Division of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockolm, Sweden.

Nils Witt (N)

Dvision of Cardiology, Department of Clinical Science and Education, Karolinska Institute, Södersjukhuset, Stockholm, Sweden.

Ellen Ostenfeld (E)

Department of Clinical Physiology, Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden.

Bertil Lindahl (B)

Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Stefan K James (SK)

Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

David Erlinge (D)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden david.erlinge@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH